Delayed trial readouts
Studies whose primary completion date moved on ClinicalTrials.gov in the last 180 days, newest first. The primary completion date is the sponsor's own estimate of when the last participant is assessed for the primary endpoint, so it is the nearest public marker of a readout. Our daily registry check records each move the day it sees it. Upcoming dates are on the readout calendar.
Summary
521 date moves in Phase 3 and 2/3 studies: 323 later and 198 earlier. The median move later is 183 days.
Date moves
| Seen | Drug | Study | Phase | Old date | New date | Move |
|---|---|---|---|---|---|---|
| 2026-11-20 | aldesleukin | NCT01704716High Risk Neuroblastoma Study 1 of SIOP-Europe (SIOPEN) | Phase 3 | 2021-09-30 | 2025-01-30 | +1218 days |
| 2026-11-20 | Capecitabine, Gemcitabine, Eribulin mesylate | NCT06143553Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Metastatic Breast Cancer | Phase 3 | 2025-12 | 2027-12-31 | +760 days |
| 2026-11-20 | Semaglutide (Ozempic) | NCT06387199Alleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide | Phase 2/3 | 2027-01 | 2027-12 | +334 days |
| 2026-11-20 | Letrozole | NCT04111978MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO) | Phase 3 | 2027-07-01 | 2028-02-01 | +215 days |
| 2026-11-20 | Ferric derisomaltose | NCT05251493Ferric Derisomaltose (Iron Isomaltoside) Versus Iron Sucrose for Treatment of Iron Deficiency in Pregnancy | Phase 3 | 2026-12-31 | 2026-05-31 | −214 days |
| 2026-11-20 | Rifaximin SSD | NCT05071716Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis | Phase 3 | 2025-09 | 2025-12-23 | +113 days |
| 2026-11-20 | Zoledronic acid | NCT03295981Local Bisphosphonate Effect on Recurrence Rate in Extremity Giant Cell Tumor of Bone | Phase 3 | 2027-01 | 2027-04 | +90 days |
| 2026-11-20 | Oxycodone (Xtampza ER) | NCT03823534Post-Op Pain Control for Prophylactic Intramedullary Nailing. | Phase 3 | 2026-12-31 | 2027-03-31 | +90 days |
| 2026-11-20 | Goserelin | NCT07777263ADT De-escalation in Selected High-Risk Prostate Cancer Patients (ADaPPt Trial) a GROUQ Led PCS Study (PCS XIV) | Phase 3 | 2035-10 | 2035-12 | +61 days |
| 2026-11-20 | Semaglutide (Wegovy) | NCT07845994SEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years | Phase 3 | 2031-02 | 2031-03 | +28 days |
| 2026-11-19 | Anakinra | NCT05805930Therapeutic Approach in Colchicine-resistant Recurrent pEricarditis in Children | Phase 3 | 2025-06-01 | 2027-10-01 | +852 days |
| 2026-11-19 | tenofovir alafenamide (Vemlidy), Emtricitabine/tenofovir disoproxil fumarate, Lenacapavir (Sunlenca), Bictegravir | NCT06544733Study of Oral Weekly Lepetegravir (Formerly GS-1720) and Lenacapavir Pacfosacil (Formerly GS-4182) Versus Biktarvy in People With HIV-1 Who Are Virologically Suppressed | Phase 2/3 | 2028-01 | 2026-11-03 | −424 days |
| 2026-11-19 | Povetacicept | NCT07204275Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN) | Phase 2/3 | 2028-12-29 | 2029-06-27 | +180 days |
| 2026-11-19 | PF-08634404, Pembrolizumab | NCT06980272SSGJ-707 in Advanced Non-Small Cell Lung Cancer | Phase 3 | 2026-07-30 | 2026-02-01 | −179 days |
| 2026-11-19 | AND017 | NCT07494409A Study of AND017 to Evaluate Efficacy and Safety in Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Patients With Anemia | Phase 3 | 2026-10-30 | 2027-02-20 | +113 days |
| 2026-11-19 | AND017 | NCT07487727A Study of AND017 to Evaluate Efficacy and Safety in Patients With Anemia Due to Non-Dialysis-Dependent Chronic Kidney Disease (NDD-CKD) | Phase 3 | 2026-12-01 | 2027-03-01 | +90 days |
| 2026-11-19 | Dexamethasone, Cevostamab, Elotuzumab, Pomalidomide, Daratumumab, Carfilzomib | NCT07555938Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma | Phase 3 | 2028-10-31 | 2028-11-30 | +30 days |
| 2026-11-19 | tilrekimig | NCT07839884A Continuation Study of Tilrekimig in Adults With Moderate-to-Severe Long-Term Breathing Difficulty, Known by the Medical Term of Chronic Obstructive Pulmonary Disease (COPD) to Learn About This Medicine When Used for a Long Period of Time | Phase 3 | 2034-05-12 | 2034-04-21 | −21 days |
| 2026-11-19 | Depemokimab, Mepolizumab | NCT05263934Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA) | Phase 3 | 2026-09-29 | 2026-10-06 | +7 days |
| 2026-11-18 | tenofovir alafenamide (Vemlidy), lamivudine (Epivir-HBV), Tenofovir disoproxil fumarate (Viread), Doravirine, Bictegravir | NCT07075146DOR/TDF/3TC COmpared With BIC/FTC/TAF in ART-Naïve People Living With HIV and Overweight or Obesity | Phase 3 | 2026-06-05 | 2027-12-05 | +548 days |
| 2026-11-18 | INCB123667 | NCT07214779Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression | Phase 3 | 2028-11-15 | 2027-10-12 | −400 days |
| 2026-11-18 | Gemcitabine, Atezolizumab | NCT03775265Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer | Phase 3 | 2027-06-01 | 2026-07-23 | −313 days |
| 2026-11-18 | Methotrexate, etanercept | NCT03728478STep-up and Step-down Therapeutic Strategies in Childhood ARthritiS | Phase 3 | 2025-02-28 | 2025-10-31 | +245 days |
| 2026-11-18 | faricimab | NCT06790784Faricimab + PRP vs. Vitrectomy + Endolaser for Treatment of PDR | Phase 3 | 2031-08 | 2032-02 | +184 days |
| 2026-11-18 | viloxazine | NCT02736656Open-label Study to Evaluate Long-term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) | Phase 3 | 2026-09 | 2026-12 | +91 days |
| 2026-11-18 | Depemokimab | NCT07177339eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation | Phase 3 | 2029-04-30 | 2029-04-02 | −28 days |
| 2026-11-18 | Temozolomide | NCT07935889Advanced Imaging-Guided Standard Versus Dose-Intensified Radiation Therapy for the Treatment of Newly Diagnosed Glioblastoma, SAGA 2.0 Trial | Phase 3 | 2035-11-02 | 2035-11-30 | +28 days |
| 2026-11-18 | Inclisiran | NCT07102628Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes | Phase 3 | 2027-02-11 | 2027-01-16 | −26 days |
| 2026-11-18 | Tafolecimab | NCT07473960IBI306 Monotherapy in Non-Familial Hypercholesterolemia and Mixed Hyperlipidemia | Phase 3 | 2026-09-06 | 2026-08-26 | −11 days |
| 2026-11-17 | zasocitinib | NCT07250802A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis | Phase 3 | 2033-01-24 | 2034-07-03 | +525 days |
| 2026-11-17 | Iparomlimab and tuvonralimab | NCT07613567QL1706 Combined With Chemotherapy as Neoadjuvant Therapy for High-Risk Locally Advanced Cervical Cancer | Phase 3 | 2032-08-31 | 2032-12-31 | +122 days |
| 2026-11-17 | HRG2010 | NCT06596876A Study to Evaluate the Efficacy and Safety of HRG2010 in Parkinson's Disease With Motor Fluctuations | Phase 3 | 2025-10-09 | 2026-01-29 | +112 days |
| 2026-11-17 | Dostarlimab | NCT07740720A Study of the Duration of Dostarlimab in Untreated Mismatch Repair Deficient (dMMR)/ Microsatellite Instability-high (MSI-H) Locally Advanced Rectal Cancer | Phase 3 | 2029-12-12 | 2030-03-13 | +91 days |
| 2026-11-17 | Daraxonrasib, Nab-paclitaxel, Gemcitabine | NCT07491445Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma | Phase 3 | 2028-06 | 2028-04 | −61 days |
| 2026-11-14 | Oxycodone (Xtampza ER) | NCT04659317Opioid-Free Orthopaedics | Phase 3 | 2028-12 | 2026-07-20 | −865 days |
| 2026-11-14 | Rosuvastatin, Laroprovstat | NCT06834932A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of AZD0780 in Participants With Dyslipidaemia | Phase 2/3 | 2025-07-03 | 2027-02-22 | +599 days |
| 2026-11-14 | Omega-3-acid ethyl esters (Lovaza) | NCT02178410VITAL Rhythm Study | Phase 3 | 2026-10 | 2027-10 | +365 days |
| 2026-11-14 | upadacitinib | NCT05889182A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy | Phase 3 | 2028-03 | 2028-08 | +153 days |
| 2026-11-14 | Trastuzumab Emtansine, Inavolisib | NCT05894239A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer | Phase 3 | 2026-12-31 | 2027-05-03 | +123 days |
| 2026-11-14 | BGM0504 | NCT06716203A Study of BGM0504 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and Exercise | Phase 3 | 2026-11-14 | 2026-08-13 | −93 days |
| 2026-11-14 | ADSTEM | NCT07377838Study of ADSTEM Injection for Patients With Moderate to Severe Subacute and Chronic Atopic Dermatitis | Phase 3 | 2029-06 | 2029-09 | +92 days |
| 2026-11-14 | Suzetrigine | NCT07654296Assessing Suzetrigine for Pain Reduction Following Ureteroscopic Surgery | Phase 3 | 2026-12-31 | 2027-03-31 | +90 days |
| 2026-11-14 | BGM0504, Semaglutide (Ozempic) | NCT06716216A Study of BGM0504 in Participants With Type 2 Diabetes | Phase 3 | 2026-11-14 | 2026-08-25 | −81 days |
| 2026-11-14 | maralixibat | NCT06553768Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND) | Phase 3 | 2026-10 | 2026-07-29 | −64 days |
| 2026-11-14 | Bempedoic acid | NCT06780410A Clinical Study to Evaluate the Efficacy, Tolerability, and Safety of Bempedoic Acid | Phase 3 | 2025-10 | 2025-08-05 | −57 days |
| 2026-11-13 | Methylprednisolone | NCT05139849VAsopressin and STeroids in Addition to Adrenaline in Cardiac Arrest - a Randomized Clinical Trial | Phase 3 | 2027-01-31 | 2029-01-31 | +731 days |
| 2026-11-13 | Naloxone (Narcan) | NCT03616236Buprenorphine for Probationers and Parolees: Bridging the Gap Into Treatment | Phase 3 | 2026-08-31 | 2026-01-30 | −213 days |
| 2026-11-13 | Docetaxel, OSE2101 | NCT06472245Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor | Phase 3 | 2027-12-15 | 2028-05-01 | +138 days |
| 2026-11-13 | Vosoritide | NCT06455059Interventional Study of Vosoritide for the Treatment of Children With Hypochondroplasia | Phase 3 | 2026-08-01 | 2026-04-23 | −100 days |
| 2026-11-13 | Vadadustat | NCT06520826Vafseo Outcomes In-Center Experience | Phase 3 | 2026-06-30 | 2026-09-10 | +72 days |
| 2026-11-13 | Everolimus | NCT02962414Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment | Phase 3 | 2026-12-30 | 2027-02-26 | +58 days |
| 2026-11-13 | barzolvolimab | NCT06455202A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU) | Phase 3 | 2026-10 | 2026-08-04 | −58 days |
| 2026-11-13 | barzolvolimab | NCT06445023A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria | Phase 3 | 2026-10 | 2026-08-12 | −50 days |
| 2026-11-13 | Bofanglutide | NCT06728124A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Obese/Overweight Subjects | Phase 3 | 2026-05 | 2026-03-26 | −36 days |
| 2026-11-13 | Gemcitabine | NCT02135042Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA | Phase 2/3 | 2029-01-01 | 2029-01-31 | +30 days |
| 2026-11-13 | Odronextamab, Rituximab | NCT06091254A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma | Phase 3 | 2028-02-07 | 2028-02-29 | +22 days |
| 2026-11-13 | Ruxolitinib (Opzelura) | NCT06959225Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1) | Phase 3 | 2026-10-09 | 2026-10-29 | +20 days |
| 2026-11-13 | Dexamethasone, Elranatamab, Elotuzumab, Lenalidomide, Bortezomib, Pomalidomide, Carfilzomib | NCT06152575MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide) | Phase 3 | 2026-08-30 | 2026-08-26 | −4 days |
| 2026-11-13 | setmelanotide | NCT05093634EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | Phase 3 | 2025-12-22 | 2025-12-19 | −3 days |
| 2026-11-11 | Methotrexate | NCT02205762LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis | Phase 2/3 | 2026-07 | 2031-11 | +1949 days |
| 2026-11-11 | Pelacarsen | NCT05900141An Open Label Extension (OLE) Study to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230) | Phase 3 | 2028-08-24 | 2026-10-15 | −679 days |
| 2026-11-11 | Bofanglutide | NCT07292441Extension Study of the Phase 3 Clinical Study of GZR18 Injection for Weight Loss | Phase 3 | 2027-09 | 2026-09-22 | −344 days |
| 2026-11-11 | Fianlimab, Cemiplimab, Pembrolizumab | NCT05608291A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery | Phase 3 | 2026-07-27 | 2027-01-15 | +172 days |
| 2026-11-11 | Bofanglutide, Semaglutide (Ozempic) | NCT06778967A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Type 2 Diabetes Mellitus | Phase 3 | 2026-12-11 | 2026-09-18 | −84 days |
| 2026-11-11 | Tirzepatide (Zepbound) | NCT06162715GLP-1 Receptor Agonists Post-Bariatric Surgery (GRABS) Pilot Trial | Phase 2/3 | 2027-01-01 | 2026-10-10 | −83 days |
| 2026-11-11 | Ranibizumab, Bevacizumab | NCT06952452Pharmacogenomics of antiVEGF in Patients With Age-Associated Macular Degeneration (AMD) | Phase 3 | 2026-07 | 2026-05-28 | −34 days |
| 2026-11-11 | retatrutide | NCT07232719A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight | Phase 3 | 2027-07 | 2027-06 | −30 days |
| 2026-11-11 | Aflibercept | NCT06683742A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56 | Phase 3 | 2026-10 | 2026-09-09 | −22 days |
| 2026-11-11 | Cabotegravir/rilpivirine (Cabenuva) | NCT07650916A Study to Investigate Cabotegravir Ultra Long-Acting (CAB ULA) Plus Rilpivirine Ultra Long-Acting (RPV ULA) in Adults and Adolescents With HIV Who Are Virologically Suppressed | Phase 3 | 2029-09-04 | 2029-08-13 | −22 days |
| 2026-11-11 | Bofanglutide | NCT06777238A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Subjects With Type 2 Diabetes Mellitus and Poor Blood Glucose Control by Diet and Exercise | Phase 3 | 2026-08-07 | 2026-07-30 | −8 days |
| 2026-11-11 | metreleptin | NCT05164341Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects With PL | Phase 3 | 2026-07-21 | 2026-07-14 | −7 days |
| 2026-11-11 | zenagamtide, Semaglutide (Ozempic) | NCT07400107AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight | Phase 3 | 2028-12-12 | 2028-12-19 | +7 days |
| 2026-11-11 | rilzabrutinib | NCT07216079Rilzabrutinib for the Adult Participants With Chronic ITP Who Have Completed Phase 3 Study in Japan | Phase 3 | 2026-11-30 | 2026-11-25 | −5 days |
| 2026-11-10 | IncobotulinumtoxinA (Xeomin) | NCT00909883Foot Dystonia Treatment by Botulinum Toxin Injections in Parkinson Disease : Efficiency of Injections Made in Extrinsic Muscle (Flexor Digitorum Longus Muscle) Compared to Intrinsic Muscle (Flexor Digitorum Brevis or Quadratus Plantae Muscles) | Phase 3 | 2011-09 | 2013-11-12 | +803 days |
| 2026-11-10 | remibrutinib | NCT07665437An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS | Phase 3 | 2031-10-29 | 2031-10-15 | −14 days |
| 2026-11-10 | Ruxolitinib (Opzelura) | NCT06958211Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2) | Phase 3 | 2026-10-09 | 2026-10-01 | −8 days |
| 2026-11-10 | tralokinumab | NCT06311682A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis | Phase 3 | 2026-10-20 | 2026-10-16 | −4 days |
| 2026-11-08 | Bosentan | NCT02377271ENDOTHELION Study Group: Effect of Bosentan in NAION Patients | Phase 3 | 2023-12 | 2027-02 | +1158 days |
| 2026-11-08 | Tarlatamab, Durvalumab | NCT06211036Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab | Phase 3 | 2027-07-05 | 2030-04-02 | +1002 days |
| 2026-11-08 | Olanzapine (Zyprexa) | NCT06200181Effect of Olanzapine on Opioid Craving and Misuse Among Patients Receiving Opioids for Cancer-related Pain: A Pilot Double-Blind, Randomized Control Trial | Phase 3 | 2026-11-01 | 2027-11-01 | +365 days |
| 2026-11-08 | Rituximab, Obinutuzumab | NCT05786768Efficacy and Safety of Obinutuzumab Versus Rituximab in Childhood Steroid Dependant and Frequent Relapsing Nephrotic Syndrome | Phase 2/3 | 2027-10-18 | 2027-06-30 | −110 days |
| 2026-11-08 | Pertuzumab | NCT02320435A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial | Phase 3 | 2026-12-31 | 2027-03-28 | +87 days |
| 2026-11-08 | Bevacizumab | NCT07851025Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Non-Homologous Recombination Deficiency (Non-HRD) Positive Advanced Epithelial Ovarian Cancer | Phase 3 | 2030-06-18 | 2030-06-28 | +10 days |
| 2026-11-07 | Famitinib, Camrelizumab | NCT05999149A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01) | Phase 3 | 2025-08-30 | 2026-05-30 | +273 days |
| 2026-11-07 | Dostarlimab | NCT05201547Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First Line | Phase 3 | 2026-04 | 2026-10-01 | +183 days |
| 2026-11-07 | Fampridine | NCT06136728Dalfampridine Combined With Physical Therapy for Mobility Impairment in Multiple Sclerosis | Phase 3 | 2026-12 | 2027-05 | +151 days |
| 2026-11-07 | Ziltivekimab | NCT06263244Specifying the Anti-inflammatory Effects of Ziltivekimab | Phase 3 | 2026-09-04 | 2026-10-30 | +56 days |
| 2026-11-07 | Trontinemab | NCT07717411A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease | Phase 3 | 2032-09-03 | 2032-07-30 | −35 days |
| 2026-11-07 | Cemdisiran, Pozelimab, Eculizumab, Ravulizumab | NCT05133531A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor Treatment | Phase 3 | 2026-10-12 | 2026-09-28 | −14 days |
| 2026-11-06 | baricitinib | NCT05056558Efficacy and Safety of Baricitinib in Patients With Moderate and Severe COVID-19 | Phase 3 | 2022-04 | 2025-07-30 | +1216 days |
| 2026-11-06 | Quetiapine (Seroquel), Clozapine, valproate, Esketamine | NCT05603104Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure | Phase 3 | 2028-06-30 | 2026-06-24 | −737 days |
| 2026-11-06 | Dexamethasone | NCT06136624Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003) | Phase 3 | 2028-08-02 | 2028-11-30 | +120 days |
| 2026-11-06 | Aflibercept, Tabirafusp tedromer, Tarcocimab tedromer | NCT06556368A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK | Phase 3 | 2026-08 | 2026-09-02 | +32 days |
| 2026-11-06 | Furosemide (subcutaneous, SQ Innovation) | NCT07018297Early Discharge With Subcutaneous Furosemide Versus Standard Care in Acute Heart Failure | Phase 3 | 2028-08-01 | 2028-09-01 | +31 days |
| 2026-11-06 | maridebart cafraglutide, Semaglutide (Ozempic) | NCT07866066Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 Diabetes | Phase 3 | 2028-09-04 | 2028-09-06 | +2 days |
| 2026-11-05 | Hydroxychloroquine, Dexamethasone, apremilast, tocilizumab, Sarilumab, Anakinra, baricitinib | NCT02735707Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia | Phase 3 | 2026-02 | 2028-06 | +851 days |
| 2026-11-05 | Sintilimab, Nab-paclitaxel | NCT05429463Neoadjuvant Therapy of Sintilimab Combined With Chemotherapy for Resectable Squamous Cell NSCLC(neoSCORE Ⅱ) | Phase 3 | 2025-11-11 | 2026-11-30 | +384 days |
| 2026-11-05 | Sotagliflozin (Inpefa) | NCT07211802CKM For Safe Use of SGLT2i in Type 1 Diabetes | Phase 3 | 2030-07-31 | 2031-07-31 | +365 days |
| 2026-11-05 | metformin | NCT06452498Preeclampsia Intervention Netherlands | Phase 3 | 2028-04 | 2029-03-19 | +352 days |
| 2026-11-05 | Capecitabine | NCT05065957Study of Combination Therapy of D07001-Softgel Capsules and Xeloda/TS-1 in Subjects With Advanced Biliary Tract Cancer | Phase 2/3 | 2026-07 | 2025-07-31 | −335 days |
| 2026-11-05 | Rituximab, Nivolumab | NCT04759586Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma | Phase 3 | 2026-12-31 | 2027-06-30 | +181 days |
| 2026-11-05 | Monalizumab, Oleclumab, Durvalumab | NCT05221840A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer | Phase 3 | 2026-09-30 | 2027-01-08 | +100 days |
| 2026-11-05 | Dapagliflozin | NCT07295223Effect of Glp-1 and Antidiabetic sgLT2 Agents for myoCardial infarcTion and Ultrasensitive Inflammatory Surveillance (GALACTUS Trial) | Phase 3 | 2026-08 | 2026-10-30 | +90 days |
| 2026-11-05 | Albuterol sulfate (Proventil HFA), albuterol (Armstrong Albuterol HFA), fluticasone propionate | NCT06052267A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations | Phase 3 | 2026-10-31 | 2026-12-31 | +61 days |
| 2026-11-05 | fluticasone propionate | NCT06664619A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma | Phase 3 | 2026-11-02 | 2026-10-26 | −7 days |
| 2026-11-05 | Risdiplam (Evrysdi) | NCT05115110A Study to Investigate the Safety and Efficacy of RO7204239 in Combination With Risdiplam (RO7034067) in Participants With Spinal Muscular Atrophy | Phase 2/3 | 2026-10-28 | 2026-11-02 | +5 days |
| 2026-11-04 | metformin | NCT04177303Incretin Hormones in Type 1 Diabetes Mellitus;Effect of Metformin Treatment | Phase 3 | 2022-11-29 | 2024-12-31 | +763 days |
| 2026-11-04 | jaktinib | NCT05676242A Phase III Extended Clinical Trial of Jaktinib Hydrochloride Tablets in the Treatment of Moderate and Severe Atopic Dermatitis | Phase 3 | 2024-12 | 2026-03-12 | +466 days |
| 2026-11-04 | jaktinib | NCT05526222A Phase III Study of Jaktinib in Adults With Moderate and Severe Atopic Dermatitis | Phase 3 | 2026-06 | 2025-08-05 | −300 days |
| 2026-11-04 | Tobevibart (VIR-3434) | NCT06903338A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection | Phase 3 | 2026-12-31 | 2026-09-30 | −92 days |
| 2026-11-04 | dupilumab | NCT02612454Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD) | Phase 3 | 2026-10-07 | 2026-10-09 | +2 days |
| 2026-11-03 | Docetaxel, Gemcitabine, Eribulin mesylate, Sacituzumab Govitecan | NCT04579224Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer | Phase 3 | 2030-08-15 | 2026-03-05 | −1624 days |
| 2026-11-03 | Entrectinib, Alectinib, Durvalumab | NCT05170204A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC) | Phase 3 | 2030-06-16 | 2027-01-19 | −1244 days |
| 2026-11-03 | Furmonertinib | NCT05607550Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT) | Phase 3 | 2025-08-15 | 2026-10-06 | +417 days |
| 2026-11-03 | Lanifibranor | NCT04849728A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 ) | Phase 3 | 2027-09-30 | 2026-09-29 | −366 days |
| 2026-11-03 | Hydroxychloroquine | NCT05287321The Efficacy of Aspirin Combined With Hydroxychloroquine Treatment in High Risk Pregnancies for Preeclampsia | Phase 3 | 2026-12-31 | 2027-12-31 | +365 days |
| 2026-11-03 | Dexamethasone | NCT05132920Fight INflammation to Improve Outcome After Aneurysmal Subarachnoid HEmorRhage | Phase 3 | 2024-12 | 2024-09-09 | −83 days |
| 2026-11-01 | Rituximab | NCT03560011Efficacy and Safety of Immunoglobulin Associated With Rituximab Versus Rituximab Alone in Childhood-Onset Steroid-dependent Nephrotic Syndrome | Phase 2/3 | 2021-01-07 | 2022-11-04 | +666 days |
| 2026-11-01 | Bemdaneprocel (MSK-DA01) | NCT06944522A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease | Phase 3 | 2027-03 | 2028-10 | +580 days |
| 2026-11-01 | Nab-paclitaxel | NCT06115499The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer | Phase 2/3 | 2029-01-15 | 2027-12-01 | −411 days |
| 2026-11-01 | Bevacizumab | NCT07286266A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01) | Phase 3 | 2029-12-17 | 2030-07-22 | +217 days |
| 2026-11-01 | Pumitamig | NCT06616532PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer | Phase 3 | 2027-01-25 | 2027-05 | +96 days |
| 2026-11-01 | Docetaxel, Gemcitabine, Risvutatug rezetecan | NCT06935409Study of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment of Osteosarcoma After Previous Second-line Treatment Failure | Phase 3 | 2026-08-31 | 2026-06-17 | −75 days |
| 2026-11-01 | N-acetylcysteine, metformin | NCT06836128The Combined Effect of N-Acetyl Cysteine and Metformin in Polycystic Ovary Syndrome Patients | Phase 3 | 2026-02-01 | 2026-03-30 | +57 days |
| 2026-11-01 | Risvutatug rezetecan | NCT06498479ARTEMIS-008:HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer | Phase 3 | 2026-09-30 | 2026-08-20 | −41 days |
| 2026-11-01 | Docetaxel | NCT07711002Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05) | Phase 3 | 2031-06-17 | 2031-05-30 | −18 days |
| 2026-11-01 | Bevacizumab | NCT07816666Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer | Phase 3 | 2028-09-26 | 2028-09-29 | +3 days |
| 2026-11-01 | Goserelin, Methylprednisolone, Docetaxel | NCT04787744Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer | Phase 2/3 | 2026-09-30 | 2026-10-02 | +2 days |
| 2026-10-31 | Vigabatrin (Sabril) | NCT04987463Efficacy and Safety of Rapamycin Versus Vigabatrin in the Prevention of Tuberous Sclerosis Complex Symptoms in Infants | Phase 2/3 | 2026-03 | 2028-12 | +1006 days |
| 2026-10-31 | Vericiguat | NCT05714085Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036) | Phase 2/3 | 2032-04-15 | 2029-08-20 | −969 days |
| 2026-10-31 | Trastuzumab Deruxtecan | NCT07022483A Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer in Adjuvant Setting | Phase 3 | 2032-03-23 | 2030-02-26 | −756 days |
| 2026-10-31 | Trastuzumab pamirtecan, Trastuzumab Emtansine | NCT06265428A Study to Compare DB-1303/BNT323 Versus T-DM1 in Breast Cancer | Phase 3 | 2026-02 | 2027-12 | +668 days |
| 2026-10-31 | metformin | NCT05468554Evaluation of Metformin Effect on the Fertility of Women Treated With 131I for Thyroid Cancer | Phase 3 | 2026-04-30 | 2028-01-31 | +641 days |
| 2026-10-31 | Sintilimab | NCT05522231Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2) | Phase 2/3 | 2025-01 | 2026-08-28 | +604 days |
| 2026-10-31 | Tadalafil | NCT05195775Tadalafil as Adjuvant Therapy for DMD | Phase 2/3 | 2025-09-05 | 2024-04-16 | −507 days |
| 2026-10-31 | Methylprednisolone | NCT04163536Comparison of Corticosteroids vs Placebo on Duration of Ventilatory Support During Severe Acute Exacerbations of COPD Patients in the ICU | Phase 3 | 2025-10-25 | 2024-11-24 | −335 days |
| 2026-10-31 | Mevrometostat | NCT06629779A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer. | Phase 3 | 2026-12-02 | 2027-09-30 | +302 days |
| 2026-10-31 | tocilizumab, Methotrexate | NCT03892785MEthotrexate Versus TOcilizumab for Treatment of GIant Cell Arteritis: a Multicenter, Randomized, Controlled Trial | Phase 3 | 2027-01 | 2026-03-27 | −280 days |
| 2026-10-31 | Dexamethasone, Rituximab, Methotrexate | NCT03150693Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia | Phase 3 | 2027-03-01 | 2027-11-01 | +245 days |
| 2026-10-31 | Rifaximin (Xifaxan) | NCT07522255Rifaximin Treatment in Bloating Predominant Functional Bowel Disorders | Phase 3 | 2027-10 | 2028-06 | +244 days |
| 2026-10-31 | Tricaprilin | NCT05809908Tricaprilin Phase 3 ALTER-AD (Alternative-Alzheimer Disease) Study | Phase 3 | 2029-06 | 2030-01 | +214 days |
| 2026-10-31 | Docetaxel | NCT04784715Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09) | Phase 3 | 2026-11-11 | 2027-05-03 | +173 days |
| 2026-10-31 | Adebrelimab, Bevacizumab | NCT07691762A Study of TACE in Combination With SHR-8068, Adebrelimab, and Bevacizumab Versus TACE in Participants With Incurable Hepatocellular Carcinoma | Phase 3 | 2031-04 | 2031-09 | +153 days |
| 2026-10-31 | Rituximab, Venetoclax | NCT03984448Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas | Phase 2/3 | 2028-04-01 | 2028-08-13 | +134 days |
| 2026-10-31 | Telikibart | NCT06516302A Study of GR1802 in Participants With Chronic Sinusitis With Nasal Polyps | Phase 3 | 2026-03 | 2026-06-12 | +103 days |
| 2026-10-31 | Sacituzumab Tirumotecan | NCT06356311A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015) | Phase 3 | 2027-01-04 | 2026-10-19 | −77 days |
| 2026-10-31 | Mevrometostat, Docetaxel | NCT06551324A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1). | Phase 3 | 2026-12-28 | 2027-02-28 | +62 days |
| 2026-10-31 | Rademikibart | NCT06488755SIM0718 Treatment of Asthma Clinical Study | Phase 3 | 2027-02-28 | 2026-12-31 | −59 days |
| 2026-10-31 | Ranibizumab | NCT06957080A Study of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DME | Phase 2/3 | 2027-03-01 | 2027-01-11 | −49 days |
| 2026-10-31 | Ammoxetine | NCT06827431The Research of Ammoxetine Hydrochloride Enteric-coated Tablets in Subjects With Depression | Phase 3 | 2026-06-30 | 2026-07-14 | +14 days |
| 2026-10-29 | Trastuzumab Deruxtecan | NCT06174987A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s) | Phase 3 | 2026-08-03 | 2028-02-17 | +563 days |
| 2026-10-29 | hepalatide | NCT07309380Phase III Clinical Trial of Hepalatide in Patients With Chronic Hepatitis D | Phase 3 | 2027-06 | 2028-06 | +366 days |
| 2026-10-29 | Gabapentin | NCT04724252Gabapentin to Reduce Opioid Use Postoperatively (GROUP) in Children | Phase 2/3 | 2026-12-31 | 2027-12-31 | +365 days |
| 2026-10-29 | Ferric derisomaltose | NCT05407987Ferric Derisomaltose and Outcomes in the Recovery of Gynecologic Oncology: ERAS (Enhanced Recovery After Surgery) | Phase 3 | 2026-12-30 | 2027-12-30 | +365 days |
| 2026-10-29 | Pembrolizumab | NCT04534205A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1 | Phase 2/3 | 2028-08 | 2029-04 | +243 days |
| 2026-10-29 | lebrikizumab | NCT06339008A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1) | Phase 3 | 2026-09 | 2026-10-22 | +51 days |
| 2026-10-29 | Lenbelintide | NCT07784270A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight | Phase 3 | 2028-08-08 | 2028-08-09 | +1 day |
| 2026-10-28 | survodutide | NCT07855900SYNCHRONIZE®-START- A Study to Test Whether Survodutide Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight | Phase 3 | 2028-06-25 | 2029-11-06 | +499 days |
| 2026-10-28 | Ordastobart, Pembrolizumab | NCT06295731Ordastobart (INBRX-106) Add-on to Pembrolizumab in 1L HPV+ PD-L1+ R/M OPSCC (HexAgon-HN) | Phase 2/3 | 2029-05 | 2029-12 | +214 days |
| 2026-10-27 | Staccato Alprazolam | NCT05077904A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures | Phase 3 | 2026-10-31 | 2027-03-29 | +149 days |
| 2026-10-27 | Cabotegravir/rilpivirine (Cabenuva) | NCT06507059Outcomes of the PLHIV With Suboptimal Viral Suppression to Injectable Long-acting Antiretrovirals | Phase 3 | 2025-07-01 | 2025-08-06 | +36 days |
| 2026-10-27 | Dapagliflozin | NCT06783166Assessing the Clinical Outcomes of Dapagliflozin Versus Acetazolamide in Patients With Acute Heart Failure | Phase 2/3 | 2025-07-01 | 2025-07-04 | +3 days |
| 2026-10-26 | Everolimus | NCT05522231Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2) | Phase 2/3 | 2025-01 | 2026-08-28 | +604 days |
| 2026-10-26 | Ipilimumab | NCT03793166Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study | Phase 3 | 2028-01-25 | 2028-03-01 | +36 days |
| 2026-10-26 | Ravulizumab | NCT07596784Efficacy and Safety of Ravulizumab in Chinese Adults Participants With Generalized Myasthenia Gravis (gMG) | Phase 3 | 2027-08-17 | 2027-08-24 | +7 days |
| 2026-10-24 | Pembrolizumab | NCT03711032Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676) | Phase 3 | 2026-07-31 | 2028-07-31 | +731 days |
| 2026-10-24 | Rimegepant (Nurtec ODT) | NCT06616194A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine | Phase 3 | 2028-08-19 | 2030-02-26 | +556 days |
| 2026-10-24 | metformin | NCT04578652Fiber and Metformin Combination Therapy in Adolescents With Severe Obesity and Insulin Resistance | Phase 3 | 2026-09 | 2027-02 | +153 days |
| 2026-10-24 | Tolvaptan | NCT04782258A Study to See if Tolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD) | Phase 3 | 2028-07-31 | 2028-12-28 | +150 days |
| 2026-10-24 | Exemestane, Letrozole, Anastrozole, Tamoxifen (Soltamox) | NCT04906395Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer | Phase 3 | 2026-11-30 | 2027-01-30 | +61 days |
| 2026-10-24 | Aficamten | NCT07023341A Study to Learn More About How Well Aficamten Works in Japanese Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy | Phase 3 | 2026-08-31 | 2026-07-14 | −48 days |
| 2026-10-24 | pemetrexed | NCT04129502TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations | Phase 3 | 2026-10-31 | 2026-09-22 | −39 days |
| 2026-10-23 | Gemcitabine | NCT06115499The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer | Phase 2/3 | 2029-01-15 | 2027-12-01 | −411 days |
| 2026-10-23 | Gemcitabine | NCT07286266A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01) | Phase 3 | 2029-12-17 | 2030-07-22 | +217 days |
| 2026-10-23 | Pertuzumab, Trastuzumab Deruxtecan | NCT04784715Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09) | Phase 3 | 2026-11-11 | 2027-05-03 | +173 days |
| 2026-10-23 | HB0017 | NCT06477237Study of Efficacy and Safety of HB0017 in Patients With Moderate to Severe Plaque Psoriasis | Phase 3 | 2024-08 | 2024-11-15 | +106 days |
| 2026-10-23 | Docetaxel | NCT06356311A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015) | Phase 3 | 2027-01-04 | 2026-10-19 | −77 days |
| 2026-10-22 | Capecitabine, Eribulin mesylate, Sacituzumab Tirumotecan, Nab-paclitaxel | NCT06279364A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer | Phase 3 | 2026-07 | 2027-04 | +274 days |
| 2026-10-22 | Dexamethasone, CT-P44, Lenalidomide, Daratumumab | NCT06952478A Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma | Phase 3 | 2027-11-15 | 2027-03-08 | −252 days |
| 2026-10-22 | AZD0120, Lenalidomide | NCT07735637A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6). | Phase 3 | 2028-10-11 | 2028-11-02 | +22 days |
| 2026-10-21 | N-acetylcysteine | NCT03900988Intravenous N-acetylcysteine and Oseltamivir Versus Oseltamivir in Adults Hospitalized With Influenza and Pneumonia | Phase 3 | 2025-10-31 | 2027-10-31 | +730 days |
| 2026-10-21 | Fruquintinib, Axitinib | NCT05522231Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2) | Phase 2/3 | 2025-01 | 2026-08-28 | +604 days |
| 2026-10-21 | SHR-1918 | NCT07349615A Study of SHR-1918 In Participants With Hypertriglyceridemia | Phase 3 | 2027-11 | 2027-03 | −245 days |
| 2026-10-20 | Methotrexate | NCT05600426A Trial Comparing Unrelated Donor BMT With IST for Pediatric and Young Adult Patients With Severe Aplastic Anemia (TransIT, BMT CTN 2202) | Phase 3 | 2029-12 | 2026-08-06 | −1213 days |
| 2026-10-20 | Cetuximab, Pembrolizumab | NCT06589804Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment | Phase 3 | 2029-11-30 | 2032-12-25 | +1121 days |
| 2026-10-20 | Gemcitabine, pemetrexed, Pembrolizumab | NCT04267848Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO]) | Phase 3 | 2027-01-31 | 2030-01-31 | +1096 days |
| 2026-10-20 | metformin | NCT06763328Metformin for the Treatment of Insulin Resistance in Women With Stage I-III Breast Cancer Completing Chemotherapy | Phase 3 | 2029-06-16 | 2031-06-16 | +730 days |
| 2026-10-20 | Afrezza | NCT06535789Inhaled Insulin vs Rapid-acting Injections for Post-meal Glucose Control in Women With Gestational Diabetes | Phase 2/3 | 2025-07 | 2026-09-05 | +431 days |
| 2026-10-20 | Aflibercept | NCT07064759Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration | Phase 3 | 2028-11 | 2027-11 | −366 days |
| 2026-10-20 | Dexamethasone, Etentamig, Lenalidomide, Daratumumab | NCT07095452A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant | Phase 2/3 | 2040-09 | 2041-03 | +181 days |
| 2026-10-20 | tanruprubart | NCT07020819An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (FORWARD Study) | Phase 3 | 2026-12-31 | 2027-05-31 | +151 days |
| 2026-10-20 | tradipitant | NCT06836557Open Label Safety Study of Tradipitant in Idiopathic and Diabetic Gastroparesis | Phase 3 | 2025-12 | 2026-03-30 | +119 days |
| 2026-10-20 | Pembrolizumab | NCT03244384Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial Cancer | Phase 3 | 2026-10-31 | 2027-01-01 | +62 days |
| 2026-10-20 | Nivolumab, Cabozantinib | NCT03793166Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study | Phase 3 | 2028-01-25 | 2028-03-01 | +36 days |
| 2026-10-17 | upadacitinib | NCT06332534Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease | Phase 3 | 2027-06 | 2031-01 | +1310 days |
| 2026-10-17 | Benralizumab | NCT06750289Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment | Phase 3 | 2028-11-03 | 2026-09-21 | −774 days |
| 2026-10-17 | Dapagliflozin | NCT05944016Phase 3 Clinical Trial With Dapagliflozin in Chronic Kidney Disease in Adolescents and Young Adult Patients | Phase 3 | 2026-09 | 2027-09 | +365 days |
| 2026-10-17 | dupilumab, upadacitinib | NCT06461897A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis | Phase 3 | 2030-07 | 2029-11 | −242 days |
| 2026-10-17 | Eptinezumab (Vyepti) | NCT04965675A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine | Phase 3 | 2026-09-05 | 2027-03-26 | +202 days |
| 2026-10-17 | dupilumab, upadacitinib | NCT06389136A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab | Phase 3 | 2026-08 | 2026-11 | +92 days |
| 2026-10-17 | lamivudine (Epivir-HBV), Dolutegravir | NCT04022967ANRS 12372 MODERATO Study | Phase 3 | 2025-02-05 | 2024-12-30 | −37 days |
| 2026-10-17 | deucravacitinib | NCT04908202A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs | Phase 3 | 2024-09-05 | 2024-10-10 | +35 days |
| 2026-10-17 | Cenobamate | NCT05067634Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) Seizures | Phase 3 | 2026-11 | 2026-10-02 | −30 days |
| 2026-10-17 | nemolizumab | NCT07762833Randomized, Double-blind, Placebo-controlled Study of Nemolizumab in Chinese Subjects With Moderate-to-severe Atopic Dermatitis | Phase 3 | 2027-09-28 | 2027-10-28 | +30 days |
| 2026-10-17 | Baxdrostat | NCT07007793Parent Study: A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary Aldosteronism Sub-study: A Follow-up Substudy After Completion of the BaxPA Main Study. | Phase 3 | 2027-08-13 | 2027-07-27 | −17 days |
| 2026-10-16 | Dapagliflozin, metformin | NCT05601336Dapagliflozin Versus Metformin and Their Combination in Polycystic Ovary Syndrome | Phase 3 | 2023-07-30 | 2026-05-01 | +1006 days |
| 2026-10-16 | BGM0504 | NCT06716203A Study of BGM0504 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and Exercise | Phase 3 | 2025-12-29 | 2026-11-14 | +320 days |
| 2026-10-16 | BGM0504, Semaglutide (Ozempic) | NCT06716216A Study of BGM0504 in Participants With Type 2 Diabetes | Phase 3 | 2026-03-20 | 2026-11-14 | +239 days |
| 2026-10-16 | Pembrolizumab | NCT07286266A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01) | Phase 3 | 2029-12-17 | 2030-07-22 | +217 days |
| 2026-10-16 | Capecitabine, Fulvestrant, Eribulin mesylate, Alpelisib (BYL719) | NCT05063786Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in PIK3CA-mutated HER2+ Advanced BC (ALPHABET) | Phase 3 | 2026-06 | 2025-12-23 | −160 days |
| 2026-10-16 | BGM0504 | NCT06704581A Study of BGM0504 Injection in Participants With Obesity or Overweight | Phase 3 | 2025-11-27 | 2026-03-17 | +110 days |
| 2026-10-16 | pemetrexed, Datopotamab Deruxtecan, Osimertinib | NCT06417814A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | Phase 3 | 2026-09-30 | 2027-01-11 | +103 days |
| 2026-10-16 | Telitacicept | NCT06456580A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG) | Phase 3 | 2027-05 | 2027-03 | −61 days |
| 2026-10-16 | Fulvestrant, Capivasertib | NCT06764186A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in Spain | Phase 3 | 2027-12-31 | 2027-11-30 | −31 days |
| 2026-10-16 | Saruparib | NCT07711002Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05) | Phase 3 | 2031-06-17 | 2031-05-30 | −18 days |
| 2026-10-15 | Docetaxel, Goserelin | NCT03678025Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer | Phase 3 | 2028-04-01 | 2033-04-01 | +1826 days |
| 2026-10-15 | Capecitabine | NCT04495088Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer | Phase 3 | 2030-08 | 2026-07-31 | −1462 days |
| 2026-10-15 | Somatropin | NCT06103513Randomized Clinical Trial of Two Different Initial Growth Hormone Doses in Children | Phase 3 | 2025-06-10 | 2028-01-05 | +939 days |
| 2026-10-15 | Apatinib, Camrelizumab | NCT05062837Hepatectomy Combined With Camrelizumab and Apatinib in CNLC Stage IIIb HCC | Phase 2/3 | 2024-09-30 | 2026-12-30 | +821 days |
| 2026-10-15 | Gemcitabine | NCT02135042Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA | Phase 2/3 | 2026-12-01 | 2029-01-01 | +762 days |
| 2026-10-15 | Gemcitabine | NCT04574960Neoadjuvant Upper Tract Invasive Cancer Trial (NAUTICAL) | Phase 3 | 2026-12 | 2027-12 | +365 days |
| 2026-10-15 | Nivolumab, Atezolizumab | NCT06646276A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS). | Phase 3 | 2028-04-06 | 2027-08-17 | −233 days |
| 2026-10-15 | Trastuzumab Emtansine | NCT05296798A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer) | Phase 3 | 2027-10-31 | 2028-06-15 | +228 days |
| 2026-10-15 | Everolimus | NCT02962414Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment | Phase 3 | 2027-08-04 | 2026-12-30 | −217 days |
| 2026-10-15 | IncobotulinumtoxinA (Xeomin) | NCT07018713A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine | Phase 3 | 2027-10 | 2027-03 | −214 days |
| 2026-10-15 | PF-08634404 | NCT07392892Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer | Phase 2/3 | 2032-01-15 | 2031-07-22 | −177 days |
| 2026-10-15 | Pumitamig, Atezolizumab | NCT06712355Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer | Phase 3 | 2028-12 | 2029-04 | +121 days |
| 2026-10-15 | Capsaicin (Qutenza) | NCT06023706Study Evaluating the Analgesic Efficacy of Capsaicin 8% Patches in Chronic Coccygodynia. | Phase 3 | 2027-01-08 | 2027-05-08 | +120 days |
| 2026-10-15 | Aripiprazole (Abilify), Cariprazine (QLM1016) | NCT06799559Study on the Efficacy and Safety of QLM1016 in Schizophrenia | Phase 3 | 2026-07 | 2026-10-23 | +114 days |
| 2026-10-15 | Montelukast (Singulair) | NCT06113640Montelukast in Parkinson Disease | Phase 2/3 | 2026-11-20 | 2026-08-20 | −92 days |
| 2026-10-15 | Venetoclax | NCT03836261Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL | Phase 3 | 2027-01-31 | 2027-04-30 | +89 days |
| 2026-10-15 | Calcipotriene/Betamethasone Dipropionate Cream | NCT07357831A Phase III Trial To Evaluate The Efficacy And Safety Of MC2-01 Cream Compared To CAL/BDP Gel and Vehicle In Plaque Psoriasis Subjects | Phase 3 | 2026-10-10 | 2026-08-06 | −65 days |
| 2026-10-15 | AR1001 | NCT05531526Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants With Early Alzheimer's Disease (Polaris-AD) | Phase 3 | 2026-05 | 2026-06-29 | +59 days |
| 2026-10-15 | Pelacarsen | NCT07625306Lp(a) Lowering Study of Pelacarsen (TQJ230) in Patients in the US With Elevated Lp(a) and Recent ACS (STEMI/NSTEMI) - Lp(a)FRONTIERS PEARL | Phase 3 | 2028-12-07 | 2029-01-22 | +46 days |
| 2026-10-15 | Haloperidol, Olanzapine (Zyprexa) | NCT07246187Comparing Haloperidol to Olanzapine in the Treatment of Suspected Cannabinoid Hyperemesis in the Emergency Department | Phase 3 | 2026-10-31 | 2026-09-25 | −36 days |
| 2026-10-15 | Capecitabine, Datopotamab Deruxtecan, Durvalumab, Pembrolizumab | NCT05629585A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03) | Phase 3 | 2027-09-20 | 2027-09-01 | −19 days |
| 2026-10-15 | Ruxolitinib (Jakafi), Bomedemstat | NCT06079879A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006) | Phase 3 | 2027-07-30 | 2027-07-14 | −16 days |
| 2026-10-15 | Omalizumab | NCT07816328Investigation of a Remibrutinib- and Omalizumab-based Treatment Algorithm in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Within 24 Weeks | Phase 3 | 2028-06-02 | 2028-05-24 | −9 days |
| 2026-10-15 | remibrutinib | NCT07665437An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS | Phase 3 | 2031-10-24 | 2031-10-29 | +5 days |
| 2026-10-15 | remibrutinib | NCT06846281Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis. | Phase 3 | 2029-07-24 | 2029-07-25 | +1 day |
| 2026-10-14 | Denosumab (Prolia) | NCT04547348The DENOCHARCOT Trial | Phase 3 | 2025-10-01 | 2030-08-01 | +1765 days |
| 2026-10-14 | Cemiplimab, Nivolumab, Pembrolizumab, Atezolizumab | NCT05317858Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets | Phase 3 | 2027-06-01 | 2031-06-01 | +1461 days |
| 2026-10-14 | diazoxide choline | NCT05701774Open-Label Extension Study of DCCR in Patients With Prader-Willi Syndrome | Phase 3 | 2028-06 | 2026-01-12 | −871 days |
| 2026-10-14 | Letrozole | NCT05316935GnRHa + Letrozole in Non-obese Progestin-insensitive Endometrial Cancer and Atypical Hyperplasia Patients | Phase 2/3 | 2026-03-30 | 2028-03-30 | +731 days |
| 2026-10-14 | Letrozole | NCT06379113GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Cancer Patients | Phase 2/3 | 2026-03-30 | 2028-03-30 | +731 days |
| 2026-10-14 | Docetaxel | NCT07821684A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants Previously Treated, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer | Phase 3 | 2031-04 | 2030-03 | −396 days |
| 2026-10-14 | Aficamten | NCT04848506Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM | Phase 2/3 | 2028-03 | 2029-03 | +365 days |
| 2026-10-14 | Nivolumab | NCT06022861A Study to Compare the Efficacy and Safety of LY01015 and Opdivo® Combined Respectively With Chemotherapy in Advanced or Metastatic Esophageal Squamous Cell Carcinoma | Phase 3 | 2025-06 | 2026-05-17 | +350 days |
| 2026-10-14 | BGM0504, Semaglutide (Ozempic) | NCT07064486A Study of BGM0504 in Participants With Type 2 Diabetes in Indonesia | Phase 3 | 2026-07-31 | 2027-04-30 | +273 days |
| 2026-10-14 | Docetaxel | NCT03178552A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) | Phase 2/3 | 2026-10-31 | 2027-06-30 | +242 days |
| 2026-10-14 | Nivolumab | NCT07392892Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer | Phase 2/3 | 2032-01-15 | 2031-07-22 | −177 days |
| 2026-10-14 | Atezolizumab, Bevacizumab | NCT05482516Evaluating Novel Therapies in ctDNA Positive GI Cancers | Phase 3 | 2026-12 | 2026-08-20 | −103 days |
| 2026-10-14 | Azetukalner | NCT06775379A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder | Phase 3 | 2026-08 | 2026-10 | +61 days |
| 2026-10-14 | onabotulinumtoxinA | NCT05878951Examining the Effects of Intra-detrusor Botox at Time of HoLEP in Men With Overactive Bladder Symptoms | Phase 2/3 | 2026-09-01 | 2026-10 | +30 days |
| 2026-10-14 | Depemokimab | NCT05334368Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial | Phase 3 | 2027-11-24 | 2027-10-29 | −26 days |
| 2026-10-14 | Docetaxel | NCT05132075Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer | Phase 3 | 2026-08-25 | 2026-09-03 | +9 days |
| 2026-10-14 | remibrutinib | NCT07816328Investigation of a Remibrutinib- and Omalizumab-based Treatment Algorithm in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Within 24 Weeks | Phase 3 | 2028-06-02 | 2028-05-24 | −9 days |
| 2026-10-14 | Esomeprazole | NCT05267613Endoscopic Evidence of Maintenance of Healing With Oral NEXIUM in Patients 1 to 11 Years Old With Erosive Esophagitis. | Phase 3 | 2026-08-14 | 2026-08-10 | −4 days |
| 2026-10-14 | ustekinumab | NCT05299931An Open-Label Extension and Long-term Efficacy and Safety Monitoring Study of Patients With Crohn's Disease Previously Included in the Loss of RESponse to Ustekinumab Treated by Dose Escalation Study | Phase 3 | 2026-06 | 2026-05-29 | −3 days |
| 2026-10-13 | Obinutuzumab | NCT03836261Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL | Phase 3 | 2027-01-31 | 2027-04-30 | +89 days |
| 2026-10-12 | Acalabrutinib | NCT03836261Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL | Phase 3 | 2027-01-31 | 2027-04-30 | +89 days |
| 2026-10-10 | pemetrexed, Volrustomig, Pembrolizumab | NCT05984277A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer. | Phase 3 | 2029-02-28 | 2026-08-17 | −926 days |
| 2026-10-10 | Alixorexton | NCT06767683A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia | Phase 2/3 | 2028-06 | 2030-06 | +730 days |
| 2026-10-10 | Sacubitril/valsartan | NCT06693674Effect of Sacubitril-Valsartan on Cardiac Structure and Function | Phase 3 | 2026-12 | 2028-08 | +609 days |
| 2026-10-10 | garetosmab | NCT07559513A Study to Investigate the Safety, Pharmacokinetics (PK), and Efficacy of Garetosmab in Children and Adolescents With Fibrodysplasia Ossificans Progressiva (FOP) | Phase 3 | 2028-12-10 | 2030-07-08 | +575 days |
| 2026-10-10 | sonelokimab | NCT06641076Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug | Phase 3 | 2027-02-04 | 2026-05-28 | −252 days |
| 2026-10-10 | Zimislecel | NCT04786262A Safety, Tolerability, and Efficacy Study of VX-880 and VX-017 in Participants With Type 1 Diabetes | Phase 3 | 2027-06-30 | 2027-12-31 | +184 days |
| 2026-10-10 | metformin | NCT02275845Medico-GDM Trial - Metformine to Prevent Gestational Diabetes Mellitus | Phase 3 | 2016-09 | 2017-03-03 | +183 days |
| 2026-10-10 | sonelokimab, risankizumab | NCT06641089Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response | Phase 3 | 2027-01-15 | 2027-01-04 | −11 days |
| 2026-10-09 | Azetukalner | NCT05716100A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3) | Phase 3 | 2026-10 | 2028-01 | +457 days |
| 2026-10-09 | Bevacizumab, Atezolizumab | NCT03148418A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A) | Phase 3 | 2026-12-31 | 2026-11-30 | −31 days |
| 2026-10-07 | Lecanemab | NCT03887455A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease | Phase 3 | 2029-06-30 | 2026-12-31 | −912 days |
| 2026-10-07 | Vildagliptin | NCT02849899Prevention of Diabetes After Transplantation by Vildagliptin in the Early Post-transplant Period | Phase 3 | 2024-07 | 2026-06-05 | +704 days |
| 2026-10-07 | Vonaprument | NCT06510816A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA) | Phase 3 | 2026-10-31 | 2027-07-31 | +273 days |
| 2026-10-07 | fluticasone propionate | NCT06664619A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma | Phase 3 | 2026-09-19 | 2026-11-02 | +44 days |
| 2026-10-07 | Elismetrep | NCT07816367A Study to Assess the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine | Phase 3 | 2027-09 | 2027-10 | +30 days |
| 2026-10-07 | maridebart cafraglutide | NCT07225686Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy | Phase 3 | 2027-09-03 | 2027-08-20 | −14 days |
| 2026-10-07 | tilrekimig | NCT07772921A Study to Learn About the Study Medicine Called Tilrekimig in People With Severe Asthma | Phase 3 | 2029-06-12 | 2029-06-01 | −11 days |
| 2026-10-07 | tilrekimig, dupilumab | NCT07783425A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe Eczema | Phase 3 | 2028-08-29 | 2028-09-08 | +10 days |
| 2026-10-06 | Telisotuzumab Adizutecan, pemetrexed, Osimertinib | NCT07005102A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer | Phase 2/3 | 2031-12 | 2036-11 | +1797 days |
| 2026-10-06 | Abemaciclib | NCT04967521SARC041: Study of Abemaciclib Versus Placebo in Patients With Advanced Dedifferentiated Liposarcoma | Phase 3 | 2025-12 | 2027-12 | +730 days |
| 2026-10-06 | Finerenone | NCT06058585The Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect | Phase 3 | 2028-08-30 | 2029-12-31 | +488 days |
| 2026-10-06 | Telisotuzumab Adizutecan, Ramucirumab | NCT07821684A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants Previously Treated, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer | Phase 3 | 2031-04 | 2030-03 | −396 days |
| 2026-10-06 | Calderasib, Pembrolizumab | NCT06345729A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004) | Phase 3 | 2029-02-19 | 2028-01-24 | −392 days |
| 2026-10-06 | Haloperidol, Olanzapine (Zyprexa) | NCT04833023HALO Trial: Haloperidol vs Olanzapine in Hyperactive Delirium in Palliative Care Patients; A Multi-Centre, Randomised-Controlled Trial | Phase 3 | 2024-12 | 2025-09-25 | +298 days |
| 2026-10-06 | Depemokimab | NCT06961214Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2) | Phase 3 | 2029-08-21 | 2028-12-13 | −251 days |
| 2026-10-06 | Depemokimab | NCT06959095Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation | Phase 3 | 2029-08-20 | 2028-12-13 | −250 days |
| 2026-10-06 | Emestedastat | NCT06125951Effect of 10 mg Xanamem on Dementia Due to Alzheimer's Disease | Phase 2/3 | 2026-10 | 2026-09-22 | −9 days |
| 2026-10-03 | Exemestane, Letrozole, Fulvestrant, Everolimus, Anastrozole | NCT07024173A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer | Phase 3 | 2026-12 | 2027-08 | +243 days |
| 2026-10-03 | Giredestrant, Docetaxel, Pertuzumab | NCT05296798A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer) | Phase 3 | 2027-12-31 | 2028-06-15 | +167 days |
| 2026-10-03 | Isatuximab | NCT07732712Isa-VRdlite for of Frail and/or Much Older Patients With High Risk Newly Diagnosed Multiple Myeloma Base on Circulating Plasma Cells | Phase 2/3 | 2028-08-01 | 2028-12-31 | +152 days |
| 2026-10-03 | afimkibart | NCT06588855A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis | Phase 3 | 2027-01-30 | 2026-10-29 | −93 days |
| 2026-10-03 | Anifrolumab | NCT07691970Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment | Phase 3 | 2032-12-31 | 2032-12-30 | −1 day |
| 2026-10-02 | Dapagliflozin | NCT06759077Cardio Protective Effect of SGL2I in Hemodialysis Patients and Its Impact on Patient Quality of Life | Phase 3 | 2024-12-28 | 2026-03-28 | +455 days |
| 2026-10-02 | Tretinoin | NCT06447480Clinical Trial to Compare Oral Isotretinoin to Standard of Care in Moderate Acne Skin of Color Patients | Phase 3 | 2026-09-01 | 2027-09-01 | +365 days |
| 2026-10-02 | Ipilimumab, Nivolumab | NCT07338981The Impact of Time-of-day-Dependent Administration of Nivolumab-Ipilimumab (ICI/ICI) Combination on Overall Survival in Adults With Advanced Kidney Cancer: A Pragmatic Multicenter, Randomized Controlled Trial. | Phase 3 | 2030-12 | 2031-12 | +365 days |
| 2026-10-02 | elecoglipron | NCT07775404A Study to Investigate the Efficacy and Safety of Elecoglipron in Asian Participants With Obesity or Overweight With or Without Type 2 Diabetes Mellitus | Phase 3 | 2027-06-04 | 2028-04-06 | +307 days |
| 2026-10-02 | Mepolizumab | NCT05030155Study of Mepolizumab-based Regimen Compared to Conventional Therapeutic Strategy in Patients With Eosinophilic Granulomatosis With Polyangiitis (E-merge) | Phase 3 | 2025-11 | 2025-02-21 | −253 days |
| 2026-10-02 | etanercept | NCT06596772A Study to Compare Efficacy, Pharmacokinetics, Safety and Immunogenicity of MB04 [Proposed Etanercept Biosimilar] to Enbrel® [EU-sourced] in Rheumatoid Arthritis | Phase 3 | 2025-10 | 2026-02-20 | +142 days |
| 2026-10-01 | Eptinezumab (Vyepti) | NCT06428838Eptinezumab as an Adjunct to Standard of Care for Migraine in an Acute Emergency Context | Phase 3 | 2025-12-30 | 2028-03 | +792 days |
Showing the newest 300 of 521 moves. Each drug page lists every registry date for its own studies.
Source: ClinicalTrials.gov, each study's record. A month-only date (YYYY-MM) is read as the first of the month, and a date that only gained or lost its day is not counted as a move. Every move we have recorded, not only the last 180 days, is a free CSV on the open data page.